Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.
Capetti A, Landonio S, Meraviglia P, Di Biagio A, Lo Caputo S, Sterrantino G, Ammassari A, Menzaghi B, Franzetti M, De Socio GV, Pellicanò G, Mazzotta E, Soria A, Meschiari M, Trezzi M, Sasset L, Celesia BM, Zucchi P, Melzi S, Ricci E, Rizzardini G. Capetti A, et al. Among authors: sterrantino g. PLoS One. 2012;7(7):e39222. doi: 10.1371/journal.pone.0039222. Epub 2012 Jul 11. PLoS One. 2012. PMID: 22808029 Free PMC article.
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A, Prinapori R, Giannarelli D, Maggiolo F, Di Giambenedetto S, Borghi V, Penco G, Cicconi P, Francisci D, Sterrantino G, Zoncada A, Monno L, Capetti A, Giacometti A; ARCA Collaborative Group. Di Biagio A, et al. Among authors: sterrantino g. J Antimicrob Chemother. 2013 Jan;68(1):200-5. doi: 10.1093/jac/dks339. Epub 2012 Aug 21. J Antimicrob Chemother. 2013. PMID: 22915463
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.
Capetti A, Meraviglia P, Landonio S, Sterrantino G, Di Biagio A, Lo Caputo S, Ammassari A, Menzaghi B, De Socio GV, Franzetti M, Soria A, Meschiari M, Sasset L, Pellicanò G, Mazzotta E, Trezzi M, Celesia BM, Melzi S, Carenzi L, Ricci E, Rizzardini G. Capetti A, et al. Among authors: sterrantino g. Int J Antimicrob Agents. 2014 Feb;43(2):189-94. doi: 10.1016/j.ijantimicag.2013.10.013. Epub 2013 Nov 15. Int J Antimicrob Agents. 2014. PMID: 24315315
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
Zaccarelli M, Fabbiani M, Pinnetti C, Borghi V, Giannetti A, Sterrantino G, Lorenzini P, Latini A, Loiacono L, Colafigli M, Ammassari A, D'Ettorre G, Plazzi M, Di Giambenedetto S, Antinori A. Zaccarelli M, et al. Among authors: sterrantino g. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19802. doi: 10.7448/IAS.17.4.19802. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397546 Free PMC article.
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C, Di Giambenedetto S, Maggiolo F, Lorenzini P, Fabbiani M, Tommasi C, Latini A, Ammassari A, Loiacono L, Sterrantino G, Bellagamba R, Boumis E, Antinori A, Zaccarelli M. Pinnetti C, et al. Among authors: sterrantino g. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19812. doi: 10.7448/IAS.17.4.19812. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397556 Free PMC article.
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort.
Pinnetti C, Di Giambenedetto S, Maggiolo F, Fabbiani M, Sterrantino G, Latini A, Lorenzini P, Ammassari A, Loiacono L, Bellagamba R, Boumis E, Cauda R, Antinori A, Zaccarelli M. Pinnetti C, et al. Among authors: sterrantino g. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):e147-50. doi: 10.1097/QAI.0000000000000727. J Acquir Immune Defic Syndr. 2015. PMID: 26090757 No abstract available.
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.
Fabbiani M, Zaccarelli M, Latini A, Sterrantino G, D'Ettorre G, Grima P, Mondi A, Rossetti B, Borchi B, Giuliani M, Antinori A, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: sterrantino g. HIV Med. 2016 May;17(5):385-9. doi: 10.1111/hiv.12313. Epub 2015 Sep 22. HIV Med. 2016. PMID: 26394902 Free article.
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Latini A, Fabbiani M, Borghi V, Sterrantino G, Giannetti A, Lorenzini P, Loiacono L, Ammassari A, Bellagamba R, Colafigli M, D'Ettorre G, Di Giambenedetto S, Antinori A, Zaccarelli M. Latini A, et al. Among authors: sterrantino g. BMC Infect Dis. 2016 Aug 11;16(1):401. doi: 10.1186/s12879-016-1703-z. BMC Infect Dis. 2016. PMID: 27515949 Free PMC article.
125 results